(S)-(+)-Ibuprofen

(S)-(+)-Ibuprofen ((S)-Ibuprofen), a S(+)-enantiomer of Ibuprofen, is a potent COX-1 and COX-2 inhibitor with IC₅₀s of 2.1 μM and 1.6 μM, respectively. (S)-(+)-Ibuprofen has analgesic, anti-inflammatory, anticancer and antipyretic effects^[1][2]. In Vitro: (S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 µM; 8 days) treatment reduces concentration dependently cell survival in both cell lines to a similar extent^[2].
(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 0-1000 µM; 20-72 hours) treatment causes a G0/G1 phase block as well as apoptosis^[2].
(S)-(+)-Ibuprofen (HCT-15 and HCA-7 cells; 900 µM; 4-72 hours) treatment shows a down regulation of cyclin A and B and an increase of the cell cycle inhibitory protein p27Kip-1^[2].
(S)-(+)-Ibuprofen inhibits COX activity, thromboxane formation, and platelet aggregation^[1].
(S)-(+)-Ibuprofen inhibits the activation of NF-κB in response to T-cell stimulation with an IC₅₀ of 61.7 μM^[3]. In Vivo: (S)-(+)-Ibuprofen (15 mg/kg/day; intraperitoneal injection; five days a week; for 4 weeks) treatment inhibits tumor growth of HCA-7 and HCT-15 xenografts in the nude mice model^[2].